181 related articles for article (PubMed ID: 30466996)
21. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.
Lee CJ; Yue CH; Lin YJ; Lin YY; Kao SH; Liu JY; Chen YH
Anticancer Res; 2014 Nov; 34(11):6467-72. PubMed ID: 25368247
[TBL] [Abstract][Full Text] [Related]
22. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
23. Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Rajagopalan P; Alahmari KA; Elbessoumy AA; Balasubramaniam M; Suresh R; Shariff ME; Chandramoorthy HC
Cancer Chemother Pharmacol; 2016 Feb; 77(2):393-404. PubMed ID: 26781309
[TBL] [Abstract][Full Text] [Related]
24. Ethyl acetate extract from Selaginella doederleinii Hieron inhibits the growth of human lung cancer cells A549 via caspase-dependent apoptosis pathway.
Sui Y; Li S; Shi P; Wu Y; Li Y; Chen W; Huang L; Yao H; Lin X
J Ethnopharmacol; 2016 Aug; 190():261-71. PubMed ID: 27292193
[TBL] [Abstract][Full Text] [Related]
25. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
26. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
Zhu K; Fang W; Chen Y; Lin S; Chen X
Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
[TBL] [Abstract][Full Text] [Related]
27. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
28. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
29. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
[TBL] [Abstract][Full Text] [Related]
30. [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
Sun Y; Ding H; Li XQ; Li L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Apr; 36(2):135-9. PubMed ID: 24791791
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.
Wang J; Wang X; Li H; Ji D; Li Y; Xu Y; Zhu Q
Bioorg Med Chem Lett; 2016 Aug; 26(16):4127-32. PubMed ID: 27353531
[TBL] [Abstract][Full Text] [Related]
32. Synergistic cytotoxicity of ampelopsin sodium and carboplatin in human non-small cell lung cancer cell line SPC-A1 by G
Lu L; Yang LN; Wang XX; Song CL; Qin H; Wu YJ
Chin J Integr Med; 2017 Feb; 23(2):125-131. PubMed ID: 27299463
[TBL] [Abstract][Full Text] [Related]
33.
Lin MX; Lin SH; Lin CC; Yang CC; Yuan SY
Anticancer Res; 2018 Jun; 38(6):3435-3445. PubMed ID: 29848694
[TBL] [Abstract][Full Text] [Related]
34. Effects of the Combination of Gliotoxin and Adriamycin on the Adriamycin-Resistant Non-Small-Cell Lung Cancer A549 Cell Line.
Manh Hung LV; Song YW; Cho SK
Mar Drugs; 2018 Mar; 16(4):. PubMed ID: 29584673
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
Li S; Li XY; Zhang TJ; Zhu J; Xue WH; Qian XH; Meng FH
Bioorg Chem; 2020 Mar; 96():103575. PubMed ID: 31962202
[TBL] [Abstract][Full Text] [Related]
36. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
[TBL] [Abstract][Full Text] [Related]
37. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
38. Ferruginol inhibits non-small cell lung cancer growth by inducing caspase-associated apoptosis.
Ho ST; Tung YT; Kuo YH; Lin CC; Wu JH
Integr Cancer Ther; 2015 Jan; 14(1):86-97. PubMed ID: 25355727
[TBL] [Abstract][Full Text] [Related]
39. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
40. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
